GLP-1 Boom Hits ASX Healthcare: 3 ASX Healthcare Stocks Reshaped by Eli Lilly’s Blockbuster Quarter

ASX Healthcare Stocks Caught in the GLP-1 Storm After Eli Lilly’s Blockbuster Quarter

Eli Lilly (NYSE:LLY) just delivered a knockout first-quarter 2026 result on Thursday, with sales of its weight-loss drug Mounjaro more than doubling and shares jumping 6% on the day. For ASX investors who still think the GLP-1 weight-loss boom is only a US story, that view is getting harder to defend. The wave is reshaping Australian healthcare, and we believe three ASX stocks deserve a closer look this week.

Why the GLP-1 Boom Now Matters for ASX Healthcare

The shift is now clear. Australia’s drug pricing committee recommended Wegovy for PBS subsidy in November 2025 for patients with heart disease and obesity, with final terms still being worked out. Eli Lilly recently walked away from a separate PBS deal for Mounjaro for diabetes after pricing fell through, but private prescriptions are already booming across the country. We believe this is a long-term shift in how healthcare dollars get spent, not a passing fad. That makes the ASX names connected to it worth paying close attention to.

EBOS Group (ASX:EBO): The Simplest Way to Play It

EBOS Group (ASX:EBO) is the largest pharmaceutical wholesaler in Australia and New Zealand, and we believe it is the cleanest GLP-1 exposure on the ASX. In its most recent half-year result, management directly named booming weight-loss drug demand as a key driver of growth. Morgan Stanley has previously flagged EBOS as a way to play this theme.

The thesis is simple. EBOS does not need to invent anything or run a clinical trial. It just needs more weight-loss prescriptions to flow through its network, and that is exactly what is happening. For income-focused investors, the steady dividend track record is a useful bonus.

Sigma Healthcare (ASX:SIG): The Higher-Beta Play

Sigma Healthcare (ASX:SIG), which now operates a network with an estimated post-merger enterprise value exceeding A$8 billion following its acquisition of Chemist Warehouse, offers higher-beta exposure to the same theme. With more than 550 Chemist Warehouse stores across Australia and a fast-growing international footprint, Sigma collects margin both at the wholesale and retail ends of every prescription. The company has been delivering strong post-merger growth, with management lifting its synergy targets along the way.

The risk here is execution. But if the PBS rollout speeds up from here, Sigma’s scale becomes a serious advantage that smaller players cannot match.

ResMed (ASX:RMD): The Contrarian Pick

ResMed (ASX:RMD) has been at the centre of an intense debate. Many investors feared GLP-1 drugs would shrink demand for sleep apnea devices, since weight loss often eases the condition. The stock has drifted lower over the past year on those fears.

But the data is starting to undermine the bear case. ResMed’s recent results show GLP-1 patients are actually more likely to start sleep apnea therapy, not less. Last Thursday, the company also delivered double-digit revenue and profit growth. We believe the short thesis is weakening faster than the share price reflects, although valuation pressure could continue in the near term.

The Investor’s Takeaway

The GLP-1 boom is no longer just an American story. EBOS offers the lowest-risk way in. Sigma is the higher-beta play. ResMed is the contrarian pick where the bear case looks shakier each quarter. In our view, distribution beats invention as the smartest way for ASX investors to ride this theme.